Suppr超能文献

评估丝氨酸蛋白酶抑制剂作为神经保护疗法的方法。

Methods for Assessing Serpins as Neuroprotective Therapeutics.

作者信息

Kwiecien Jacek M

机构信息

Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada.

Department of Clinical Pathomorphology, Medical University of Lublin, Lublin, Poland.

出版信息

Methods Mol Biol. 2018;1826:223-235. doi: 10.1007/978-1-4939-8645-3_15.

Abstract

As the systematic work on the pathogenesis of the white matter injury in the spinal cord models progresses, it becomes obvious that a severe and extraordinarily protracted, destructive inflammation follows the initial injury. Appropriate anti-inflammatory therapies of sufficient duration should not only inhibit but also lead to the elimination of this destructive inflammation, thus resulting in neuroprotection of the spinal cord tissue and a greater preservation of the neurologic function. While dexamethasone, a powerful, anti-inflammatory steroid analog administered continuously by subdural infusion for 7 days inhibited severe macrophage infiltration in the cavity of injury, the dose used was remarkably toxic. A 2-week-long infusion of lower doses of dexamethasone resulted in dose-dependent inhibition of macrophage infiltration and was better tolerated by the rats, but it became evident that a much longer duration of subdural administration of a powerful anti-inflammatory drug is required to eliminate myelin-rich, necrotic debris from the cavity and synthetic steroids such as dexamethasone, and methylprednisolone may be too toxic for this application. Therefore, nontoxic but powerful anti-inflammatory compounds are required for neuroprotective treatment of the spinal cord injury (SCI) and also brain trauma and stroke where the massive injury to the white matter occurs. Serpins have been associated with neurological damage. The mammalian serpin neuroserpin (SERPINI1) is reported to act in a protective manner after cerebrospinal infarction. The serine protease, tissue-type plasminogen activator (tPA), and the serpin plasminogen activator inhibitor (PAI-1, SERPINE1) are both upregulated at sites of central nervous system damage. In preliminary studies, subdural infusion of the myxomaviral serpin, Serp-1, resulted in the powerful inhibition of the macrophage infiltration of the cavity of injury, comparable to the inhibition by high dose of dexamethasone that has proven to be unduly toxic. Nontoxic, yet powerful neuroprotective, anti-inflammatory effects of Serp-1 may indicate this serpin protein as a potential attractive compound to treat SCI and similar syndromes involving massive injury to the white matter such as brain trauma and stroke. Novel methods of drug delivery, chronic subdural infusion, and novel analytic methods to measure the effectiveness of the neuroprotective serpin treatments are discussed in this chapter.

摘要

随着脊髓模型中白质损伤发病机制的系统性研究不断进展,显而易见的是,在初始损伤后会出现严重且极其持久的破坏性炎症。持续时间足够长的适当抗炎疗法不仅应抑制这种破坏性炎症,还应使其消除,从而对脊髓组织起到神经保护作用,并更好地保留神经功能。虽然地塞米松是一种强效抗炎类固醇类似物,通过硬膜下输注连续给药7天可抑制损伤腔内严重的巨噬细胞浸润,但所用剂量毒性显著。低剂量地塞米松持续输注2周可导致巨噬细胞浸润呈剂量依赖性抑制,且大鼠耐受性较好,但很明显,需要更长时间的硬膜下给予强效抗炎药物才能清除损伤腔内富含髓磷脂的坏死碎片,而地塞米松和甲基强的松龙等合成类固醇用于此用途时可能毒性过大。因此,脊髓损伤(SCI)以及脑外伤和中风(这些病症会发生大量白质损伤)的神经保护治疗需要无毒但强效的抗炎化合物。丝氨酸蛋白酶抑制剂(Serpins)与神经损伤有关。据报道,哺乳动物丝氨酸蛋白酶抑制剂神经丝氨酸蛋白酶抑制剂(SERPINI1)在脑脊髓梗死发生后具有保护作用。丝氨酸蛋白酶组织型纤溶酶原激活剂(tPA)和丝氨酸蛋白酶抑制剂纤溶酶原激活剂抑制剂(PAI - 1,SERPINE1)在中枢神经系统损伤部位均上调。在初步研究中,硬膜下输注黏液瘤病毒丝氨酸蛋白酶抑制剂Serp - 1可强效抑制损伤腔内的巨噬细胞浸润,其抑制效果与已证明毒性过大的高剂量地塞米松相当。Serp - 1无毒但具有强大的神经保护抗炎作用,这可能表明这种丝氨酸蛋白酶抑制剂蛋白是治疗SCI以及类似涉及大量白质损伤的综合征(如脑外伤和中风)的潜在有吸引力的化合物。本章讨论了药物递送的新方法、慢性硬膜下输注以及测量神经保护丝氨酸蛋白酶抑制剂治疗效果的新分析方法。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验